Our Story

Since 2006, Spectrum Solutions has been a single-source provider of high-quality, direct-to-consumer product innovation & global fulfillment. For the last decade, Spectrum has found a specialized focus building on its medical and non-medical product development and manufacturing expertise by integrating complete test-to-treat partner solutions adding clinical laboratory testing with an onsite compounding pharmacy. Spectrum’s innovation has made such an impact within the life science sector it has been honored with several prestigious awards, received incredible industry and private sector recognition, and is directly responsible for the birth of a new billion-dollar saliva diagnostic industry.

Sometimes, a fresh perspective on something we thought we understood can open the door to new possibilities we hadn’t even considered. Focused on empowering complete wellness, Spectrum Solutions commissioned the breakthrough saliva study that dared to suggest a complete transformation in viral PCR testing protocols to an easier, pain-free, non-invasive, 99.998% accurate, inactivating any live virus in under 10 seconds, and infinitely safer option using saliva (spit).

Saliva’s recent MVP status is a new development even though saliva’s been used in diagnostics for more than 2000 years. Analysis of the properties in saliva using biochemical and physiological methodologies are traced back to at least a century ago. Unlike blood, saliva analysis looks at the cellular level (the biologically active compounds), making it a better representative of what is clinically relevant.

Years from now, the medical community, patients, and history books will look back on 2020 and COVID-19 testing as the diagnostic turning point in favor of saliva.

In affirmation of this diagnostic innovation pivot, a speedy and unprecedented FDA response secured the first Emergency Use Authorization (EUA) early March 2020, for the use of saliva, solely collected using the Spectrum SDNA-1000, as a diagnostic biomaterial for COVID-19 testing.